DE60312333D1 - Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung - Google Patents
Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellungInfo
- Publication number
- DE60312333D1 DE60312333D1 DE60312333T DE60312333T DE60312333D1 DE 60312333 D1 DE60312333 D1 DE 60312333D1 DE 60312333 T DE60312333 T DE 60312333T DE 60312333 T DE60312333 T DE 60312333T DE 60312333 D1 DE60312333 D1 DE 60312333D1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical composition
- solid pharmaceutical
- production
- composition containing
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0207831 | 2002-06-25 | ||
FR0207831A FR2841138B1 (fr) | 2002-06-25 | 2002-06-25 | Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation |
PCT/FR2003/001933 WO2004000279A1 (fr) | 2002-06-25 | 2003-06-24 | Composition pharmaceutique solide contenant un principe actif lipophile, son procédé de préparation |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60312333D1 true DE60312333D1 (de) | 2007-04-19 |
DE60312333T2 DE60312333T2 (de) | 2007-12-20 |
Family
ID=29720010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60312333T Expired - Fee Related DE60312333T2 (de) | 2002-06-25 | 2003-06-24 | Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080095838A1 (de) |
EP (1) | EP1521574B1 (de) |
JP (1) | JP2005533802A (de) |
KR (1) | KR20050040869A (de) |
AT (1) | ATE355829T1 (de) |
AU (1) | AU2003260621A1 (de) |
CA (1) | CA2490341A1 (de) |
DE (1) | DE60312333T2 (de) |
ES (1) | ES2283821T3 (de) |
FR (1) | FR2841138B1 (de) |
WO (1) | WO2004000279A1 (de) |
ZA (1) | ZA200500716B (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL130602A0 (en) | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
CN101389315A (zh) * | 2004-06-17 | 2009-03-18 | 莫茨药物股份两合公司 | 美金刚口服剂型即释制剂 |
US8367105B2 (en) | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
EP1830830A4 (de) * | 2004-12-06 | 2010-02-10 | Reliant Pharmaceuticals Inc | Omega-3-fettsäuren und dyslipidämisches mittel für die lipidtherapie |
CA2608690C (en) | 2005-05-18 | 2016-07-05 | Dainippon Sumitomo Pharma Co., Ltd. | Stable tablet containing droxidopa |
US20070238746A1 (en) | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
US20090074872A1 (en) * | 2006-06-26 | 2009-03-19 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
AU2007265452A1 (en) * | 2006-06-26 | 2008-01-03 | Mutual Pharmaceutical Company, Inc. | Active agent formulations, methods of making, and methods of use |
CA2664641A1 (en) | 2006-09-26 | 2008-04-10 | Astellas Pharma, Inc. | Controlled release dosage form of tacrolimus |
CA2674039A1 (en) * | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | Sustained release formulation for tacrolimus |
WO2009140341A2 (en) * | 2008-05-13 | 2009-11-19 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
JP5583012B2 (ja) * | 2008-06-13 | 2014-09-03 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
US20100159010A1 (en) * | 2008-12-24 | 2010-06-24 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
JP5953646B2 (ja) * | 2009-11-24 | 2016-07-20 | 大正製薬株式会社 | イブプロフェン含有固形製剤 |
JP5508311B2 (ja) * | 2011-02-28 | 2014-05-28 | テバ ファーマシューティカル インダストリーズ リミティド | 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態 |
HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP2902029B1 (de) | 2012-09-25 | 2018-08-08 | Chugai Seiyaku Kabushiki Kaisha | Ret-inhibitor |
FR2997627B1 (fr) * | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant de l'ulipristal acetate |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
CA2946518C (en) | 2014-04-25 | 2022-07-26 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
BR112017013982A2 (pt) | 2015-01-16 | 2018-01-02 | Chugai Seiyaku Kabushiki Kaisha | fármaco de combinação |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | ステロイドホルモン薬学的組成物 |
WO2019034712A1 (en) | 2017-08-17 | 2019-02-21 | F. Hoffmann-La Roche Ag | NOVEL PHARMACEUTICAL COMPOSITIONS FOR BASIC OR NEUTRAL COMPOUNDS OF LOW MOLECULAR WEIGHT |
WO2019063478A1 (en) * | 2017-09-26 | 2019-04-04 | Capsugel Belgium Nv | SUB-MICRONIC PARTICLE FORMULATIONS |
WO2020050241A1 (ja) | 2018-09-04 | 2020-03-12 | 中外製薬株式会社 | 4環性化合物の製造方法 |
CN114569605A (zh) * | 2022-03-10 | 2022-06-03 | 沈阳药科大学 | 阿托伐他汀-黄酮类化合物共无定型复合物及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0729926B2 (ja) * | 1989-07-25 | 1995-04-05 | 大塚製薬株式会社 | 易吸収性製剤用組成物 |
TW209174B (de) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
JP3696087B2 (ja) * | 1997-12-31 | 2005-09-14 | チョンワエ ファーマ コーポレーション | イトラコナゾール(itraconazole)経口用製剤及びその製造方法 |
AU3074700A (en) * | 1999-01-22 | 2000-08-07 | Yamanouchi Pharmaceutical Co., Ltd. | Medicinal compositions with improved oral absorption |
US6465011B2 (en) * | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
KR100863146B1 (ko) * | 2000-07-17 | 2008-10-14 | 아스텔라스세이야쿠 가부시키가이샤 | 경구 흡수 개선 의약 조성물 |
-
2002
- 2002-06-25 FR FR0207831A patent/FR2841138B1/fr not_active Expired - Fee Related
-
2003
- 2003-06-24 EP EP03760779A patent/EP1521574B1/de not_active Expired - Lifetime
- 2003-06-24 AT AT03760779T patent/ATE355829T1/de not_active IP Right Cessation
- 2003-06-24 JP JP2004514981A patent/JP2005533802A/ja active Pending
- 2003-06-24 AU AU2003260621A patent/AU2003260621A1/en not_active Abandoned
- 2003-06-24 KR KR1020047021343A patent/KR20050040869A/ko not_active Application Discontinuation
- 2003-06-24 ES ES03760779T patent/ES2283821T3/es not_active Expired - Lifetime
- 2003-06-24 CA CA002490341A patent/CA2490341A1/fr not_active Abandoned
- 2003-06-24 DE DE60312333T patent/DE60312333T2/de not_active Expired - Fee Related
- 2003-06-24 US US10/519,166 patent/US20080095838A1/en not_active Abandoned
- 2003-06-24 WO PCT/FR2003/001933 patent/WO2004000279A1/fr active IP Right Grant
-
2005
- 2005-01-25 ZA ZA200500716A patent/ZA200500716B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2005533802A (ja) | 2005-11-10 |
FR2841138A1 (fr) | 2003-12-26 |
FR2841138B1 (fr) | 2005-02-25 |
ATE355829T1 (de) | 2007-03-15 |
KR20050040869A (ko) | 2005-05-03 |
AU2003260621A1 (en) | 2004-01-06 |
US20080095838A1 (en) | 2008-04-24 |
EP1521574B1 (de) | 2007-03-07 |
WO2004000279A1 (fr) | 2003-12-31 |
CA2490341A1 (fr) | 2003-12-31 |
EP1521574A1 (de) | 2005-04-13 |
DE60312333T2 (de) | 2007-12-20 |
ES2283821T3 (es) | 2007-11-01 |
ZA200500716B (en) | 2006-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60312333D1 (de) | Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung | |
WO2003090726A3 (en) | Chewable soft capsule | |
BR9503386A (pt) | Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina | |
WO2004032862A3 (en) | Cyclodextrin-based materials, compositions and uses related thereto | |
EP1428821A8 (de) | Piperidin-4-ylamine mit analgetischer Wirksamkeit | |
BRPI0412975A (pt) | espuma penetrante para uso farmacêutico | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
WO2007000778A3 (en) | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof | |
HUP0004924A2 (hu) | Ciklodextrineket tartalmazó gyógyászati készítmények | |
SV2004001556A (es) | Preparaciones acidas de insulina con establidad mejorada | |
BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
CA2396159A1 (en) | Novel substituted benzimidazole dosage forms and method of using same | |
BR0103033A (pt) | Partìculas farmacêuticas de sabor mascarado | |
HUP0302086A2 (hu) | Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására | |
FR2811552B1 (fr) | Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide | |
ATE307569T1 (de) | Gelierbare pharmazeutische zusammensetzungen | |
DE60001546D1 (de) | Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
WO2003043631A3 (en) | Method for identification of tumor targeting enzymes | |
EE9900589A (et) | Farmatseutilised kompositsioonid limaskestale kandmiseks | |
BRPI0409523A (pt) | método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica | |
CY1110906T1 (el) | Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης | |
ATE326264T1 (de) | Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung | |
DE60019334D1 (de) | Antivirale arznei | |
DE50004443D1 (de) | Wirkstoffhaltige komposition sowie deren herstellung und verwendung | |
BR9913135A (pt) | Formulação oral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |